- Zimmer Biomet (ZBH) to acquire Monogram Technologies (MGRM, Financial) with an upfront payment of $4.04 per share, equating to approximately $177 million in equity value.
- The acquisition will enhance Zimmer Biomet's ROSA® Robotics platform by integrating Monogram's FDA-cleared semi-autonomous technologies.
- The deal is expected to close by the end of 2025 and is projected to be accretive to earnings starting in 2028, contributing to revenue growth from 2027.
Zimmer Biomet (ZBH), a pioneering force in medical technology, has announced a definitive agreement to acquire Monogram Technologies (MGRM) for $4.04 per share, translating to an equity value of around $177 million. This acquisition will integrate Monogram's semi-autonomous robotic technologies into Zimmer Biomet's ROSA® Robotics platform, aiming to expand the company's capabilities in orthopedic surgical robotics.
The acquisition includes a contingent value right (CVR) of up to $12.37 per share, contingent on achieving specific development milestones by 2030. Monogram's technology, which navigates total knee arthroplasty via CT-based, semi-autonomous AI, is anticipated to be commercialized with Zimmer Biomet's implants by early 2027. This deal positions Zimmer Biomet to potentially become the first company to offer fully autonomous surgical robots in orthopedics.
Financially, the transaction is planned to be neutral to adjusted earnings per share (EPS) from 2025 through 2027 and is expected to become accretive starting in 2028. Revenue contributions are projected to begin in 2027, aligning with the typical adoption cycles in medical technology. Completion of this merger is pending regulatory and shareholder approvals, with a closing expected later in 2025.
